

Cambridge University Press

0521546664 - Pharmaceutical Reason: Knowledge and Value in Global Psychiatry

Andrew Lakoff

Index

[More information](#)

Index

- Abbott Pharmaceuticals 23, 108, 171
Acta Neuropsiquiatria Argentina 46, 64
 Alder, Ken 40
American Journal of Psychiatry 5, 64, 123
 American Psychiatric Association (APA)
 1, 7, 11, 24, 63, 64, 148
 Andreasen, Nancy 5
 anti-depressants 114, 129, 132, 135, 136, 138,
 150, 151, 152, 154, 155, 156, 157, 158,
 162, 163, 165
 sales of 135
 Selective Serotonin Reuptake
 Inhibitors (SSRIs) 155, 156, 158,
 165, 166
 Argentina 41, 139, 141, 153
 and depression 158
 drug marketing in 134
 and globalization 55–7
 introduction of managed care 124
 lack of regulation 20, 27
 mental health policy 121
 mental health reform 48–50
 obstacles to standardization in 39
 pharmaceutical industry in
 137–8, 139
 sales of psychopharmaceuticals 152–7
 scientific research in 27
 Armando, Jacinto 76, 77, 79, 109
Asociación de Psiquiatras Argentinos (APsA)
 63, 67, 109
Asociación Psicoanalítica Argentina (APA)
 58, 74, 75, 78, 164
 audit 146
 and surveillance 138
 as a technology of mistrust 145
 authorship 90
 Barenbilt, Valentin 67
 Bierer, Joshua 47
 bioethics 27
 biomedical psychiatry 4, 6, 10, 13, 17, 58, 59,
 82, 150, 162
 in Argentina 104
 critiques of 106
 and the Diagnostic and Statistical Manual
 (DSM) 12–13
 and the human 86, 106
 biomedicine 5, 15, 104
 and rights of patients 117
 biopolitics 19, 120, 122, 124,
 136, 170
 and formation of populations 19, 24, 35,
 39, 122, 136, 173
 and the market 171
 biosociality 31
 biotech industry 1, 19, 20, 171
 bipolar disorder 1, 2, 18, 22–3, 32, 36, 60, 97,
 101, 116, 174
 in Argentina 2, 25, 116
 classification of 116
 diagnosis of 21, 24, 25–6, 36, 97–8, 99–100,
 117, 128–33
 DSM definition of 24
 and genetic markers (SNPs) 24
 and genetic risk 31
 genetics of 37
 history of 33–5
 and psychosis 101
 and schizophrenia 112
 type I 24
 type II 24
 see also manic depression
 bipolar identity 40, 108

Cambridge University Press

0521546664 - Pharmaceutical Reason: Knowledge and Value in Global Psychiatry

Andrew Lakoff

Index

[More information](#)

Index

201

- Borch-Jakobsen, Mikkel 158, 162
 reinterpretation of Anna O. 162
- Borges, Jorge Luis 16
- Borón, Atilio 56
- Boston Consulting Group (BCG) 168, 169,
 170, 171
- boundary objects 13
- Bowker, Geoffrey 13
- Boyle, James 20
- Breuer, Joseph 161
- brief therapy 124
- Campomar Institute 22, 26
- Canguilhem, Georges 5, 175
- Carruthers, Bruce 21
- Castel, Robert 117, 121
- citizenship 45, 46, 67–72
- classification 18, 31, 116–18, 131, 168
 and authority 116
 in the human sciences 3
 and liquidity 21–2
 of markets 143
 of mental illness 33–5
 and sub-populations 170, 174
- clinical trials 53–4, 148, 173
- Close Up 142, 144–5, 150, 152
- Cohen, Daniel 27, 175
- Collins, Francis 30
- commensuration 61
 challenges to 20
- consumer identity 108, 117, 118, 139,
 169
 and citizenship 70
 and expertise 140
- Cordobazo* 75
- cosmetic psychopharmacology 83
- Cronon, William 21
- “Decade of the Brain” 4, 68
- decode Genetics 29
- dehumanization 107, 112, 127
 and technology 176
- Deleuze, Gilles 3, 137
- depression 126, 157–8, 162, 163
- desarollismo* 45, 70
- developmentalist modernization
 (*see* *desarollismo*)
- diagnosis 11, 21, 163, 166, 170, 174
 cross-national disparity 34–5
 diagnostic criteria 20
 diagnostic standards 72
 and history of drug discovery 117
 and professional authority 118
 and psychic structure 94
 and the therapeutic trial 162
- diagnostic nominalism 115, 117
- Diagnostic and Statistical Manual
 (DSM) 12, 13–14, 57, 72, 97,
 104, 112, 131, 151,
 164, 165
 and formation of populations 122
 and genetic research protocol 24, 35
 and globalization 60
 history of 40
 resistance to 36, 57–8, 60, 61, 64
- disease management 169
- disease specificity 10–11, 13
- DNA 1, 18, 19, 21, 22, 24, 25, 26, 160
 cDNA library 22
- doctor–patient relationship 1–2, 85–6, 93
 and biomedical psychiatry 104
 and diagnosis 116
- drug development 173
 and drug target 161, 175
 and marketing 140
- epidemiology 135, 136, 137, 155, 157
 in Argentina 121
 transnational 2, 20
- epistemic milieu 42, 149, 158
- epistemic resistance 62–6
- epistemology 46–7, 123
 and bipolar disorder 97
 and ethics 111
- Espelund, Wendy 61
- Esquirol, Jean-Etienne-Dominique 33
- essential suffering 106
- ethics 5, 72, 149
 and biotechnology 29
 and clinical research 26
 conflict of interest 140, 141, 157
 and epistemology 111
 and neuroscience 118
 and psychoanalysis 127
 and social reintegration 71
 and technology 14
- Evita Hospital *see* Lanús
- Ewald, François 13
- expertise 3–4, 9, 17, 44, 48, 60, 85,
 108, 121, 122, 136, 140, 150, 163–4,
 168, 169
 epistemology of 46–7

- expertise (cont.)
 and marketing 140
 and prescription audits 135
- Food and Drug Administration (FDA) 10, 11
- Ferrer, Aldo 56
- Forrester, John 87, 90
- Foucault, Michel 51
 and the author function 90
 and biopolitics 19, 170
 genealogy of governmental rationality 136
 history of psychiatry 106
- Freud, Sigmund 76, 87, 90, 92, 94, 97,
 106, 128, 167
 discovery of the unconscious 92
 neurosis and psychosis 46, 61, 94–5,
 96, 164
Studies on Hysteria 161, 162
 talking cure 162
- Fundación Bipoles de Argentina* (FUBIPA)
 26, 99, 108, 111
- Gador 51, 52, 136, 139, 150
 and drug licensing 151
 globalization ad campaign 151
 vulnerability ad campaign 151–2
- Galli, Vicente 69
- GATT (General Agreement of Trade and
 Tariffs) 138
- gene, conceptions of 160
- gene-chip 174
- genomics 3, 18, 19, 23, 169
 critiques of transnational research in 28
 database firms 19–20
 goals of research 30
 and political rationality 31
 and self-formation 31
see also pharmacogenomics
- Genset 18, 20, 22–5, 27–30, 32–3, 36, 40, 160,
 161, 167, 171, 172, 174
 and gene discovery program 1, 23
 and Hospital Romero 23
 research strategy 29
- gift exchange 140, 141, 145
- Ginzburg, Carlo 89
- Giorgi, Victor 70
- globalization 4, 41, 43, 56, 64, 68, 122,
 150, 151
 interpreted as cultural imperialism 56
 and neoliberalism 56
 and psychiatry 57
- Goldenberg, Mauricio 48, 66
- Guattari, Félix 3
- Hacking, Ian 3
- Healy, David 157, 162
- Heidegger, Martin 63
- Hirsch, Hugo 124
- Hospital Borda 50, 52, 139
- Hospital Romero 1, 7, 15, 22, 25, 36,
 73, 78, 81, 82, 88, 97, 112, 119,
 126, 127
 institutional structure of 103
- Hughes, Thomas 10
- Human Genome Project 19, 20, 23, 27, 30,
 31, 160, 161, 168, 170, 172
- human, conceptions of the 4, 44, 61, 86–90,
 101, 105
 and biomedicine 71
 and expertise 3–4
 and the life sciences 106
 and neoliberalism 70
 and psychopharmaceuticals 98
 and technology 14–16, 175
- hysteria 162, 163
- IMS Health 134, 142, 143, 144, 150, 152, 156
 in Argentina 142
- inessential suffering 106
- Instituto Nacional de Salud Mental*
 (INSM) 45
- intellectual property 19, 138, 172
 in Argentina 139
 and economic value 20
 and human genes 28–9, 31
see also GATT (General Agreement of
 Trade and Tariffs)
- International Monetary Fund (IMF) 56, 123
- Janssen Pharmaceuticals 23, 148, 149, 160
- Kandel, Eric 105
- Keller, Evelyn Fox 160
- Kesselman, Hernan 69
- Klein, Melanie 53, 76
- Kline, Nathan 8
- knowledge 140
 and administration 120, 122
 audit as a form of 135
 and authorship 90
 biological knowledge and ethics 107
 and biopolitics 171

- and ethics 5
- and globalization 122
- and marketing 147, 150, 153–4
- and populations 121
- and power 137
- production in public hospitals 82–3
- and professional authority 91–4, 104, 140, 163–4
- and public hospitals 93
- question of universality 3
- and social order 135
- stabilization of facts 3, 5
- see also* epistemology
- Koselleck, Reinhardt 169
- Kraepelin, Emil 34

- Lacan, Jacques 16, 76, 78, 82, 86, 92, 94, 128
- foreclosure 95, 165
- “Name-of-the-Father” function 95
- and psychosis 95
- restitution 95
- “Rome Discourse” 53
- Seminar* 51
- lacanismo* 73, 74
- in Argentina 75–81
- as political thought 77
- and psychoanalysis in Buenos Aires 78
- and psychosis 77, 79
- and study groups 75–81
- Lagamarsino, Alejandro 108, 109
- Lanús 48, 49, 66
- Levin, Mariano 27
- Lipovetsky, Gustavo 59
- liquidity 18, 21
- and standardization 21, 41
- lithium 7, 109, 110, 111, 117
- see also* mood stabilizers
- Luhmann, Niklas 1, 169
- Luhrmann, Tanya 106, 110

- Macherey, Pierre 13
- mania 33, 97
- manic depression 7, 33, 34
- market strategists 135, 147, 153
- and the pharmaceutical market 112
- marketing 140, 158, 169
- ad campaigns 151–2
- and expertise 140
- as a post-social science 137
- and prescription audit 135
- and psychopharmaceutical consumption 156, 157
- sales rep 142
- Masotta, Oscar 76, 77, 79
- medical order 81–3
- medication 7, 8, 83, 111
- consumption of 155
- as a disciplinary technology 9, 84
- melancholia 33, 97
- Menem, Carlos 55, 139
- Mental Health Movement
- in the United States 44–5
- see also* *Salud mental*
- mental illness 47
- biological model of 83, 106, 107
- classification of 106
- definition of 7
- diagnosis of 3, 58–60
- and genes 29, 160
- genetic basis 1, 2
- genotype and phenotype 35–40, 175
- history of 33–4
- and medication 44
- and mental health reform 44
- psychodynamic model of 8, 34
- and public policy 120
- and the specificity model 174
- and “the social” 44
- Miller, Jacques-Alain 80
- molecular biology 23, 109, 160
- mood stabilizers 98, 101, 112, 115, 116, 129, 132
- see also* lithium
- mundo-psi* 3, 4, 14, 16, 75, 103
- as epistemic milieu 4
- and historical consciousness 66–7
- and market strategists 137

- neoliberalism 1, 5, 15, 50, 55, 69, 70, 123–6, 138
- and intellectual property regimes 20
- new prudentialism 31
- neurodiversity 117
- neuroscience 72, 107, 109, 120
- and ethics 118
- and psychotherapy 105
- norms 14, 26, 41, 56, 122
- biological 175
- biomedical 125
- of human conduct 5, 175
- pharmacogenomic 174–6

- norms (cont.)
 professional 13
 social 175
 of specificity 6, 163, 170
- opinion leaders 146–9, 147, 151
- PANSS (Positive and Negative Symptoms of Schizophrenia) Scale 51, 53
- paradigm 9, 43, 59, 64, 112
 cases as 90
 crisis of 62, 66
 and diagnosis 58
 of the genetic code 160
 of global psychiatry 63
 of the ‘great structures’ 63
 neuroscientific 57, 62
 and politics 69
- Pasteur Institute 22
- patents 28, 160, 163, 173
 effects of expiration 169
 on living organisms 28–9
see also intellectual property
- patient advocacy 107, 108 *see also* patient identity
- patient identity 1–2, 22, 31
 and biotechnology 3
 and illness 106, 110
 mental illness and negotiation of 31
 and professional authority 93
 and the psy-sciences 3
- Paz, Rafael 78
- peripheral modernity 16
- Perón, Juan 45, 74
- Peronism 45
- personalized medicine 168, 169, 171, 173
 and pharmacogenomics 170
see also pharmacogenomics
- pharmaceutical industry 1, 13, 138, 142, 173
 and audit 135, 143
 and “disease management” 169
 Eli Lilly 50, 136, 139
 GlaxoSmithKline 141, 156, 168
 and the market 146
 Millennium Pharmaceuticals 170
 Pfizer 156
 Roche 141
see also Abbott Pharmaceuticals; Gador; Janssen Pharmaceuticals
- pharmaceutical reason 5–7, 15, 174, 176
- pharmacogenomics 161, 167, 170, 173, 174, 175
 and clinical trials 173
 medication response 23, 174
 medication-response phenotypes 168
 as a technology 173
- pharmacology 147
- PhRMA (Pharmaceutical Research and Manufacturers of America) 139
- Pichon-Rivière, Enrique 45, 47
- Pichot, Pierre 104
- Pignarre, Philippe 162
- Plan Goldenberg* 48–50
- Plotkin, Mariano 75
- political rationality 123, 136
 and risk 121
see also neoliberalism; welfare state
- prepagos* (Prepaid Health Plans) 123, 124, 127
- prescription leaders 142, 146, 148
- professional identity 61, 74, 82, 104
 and self-formation 82
- Prozac 2, 129, 138, 165
- psyche, epistemic status of 5–6
- psychiatry 2, 5–6, 119
 in Argentina 44
 biologization of 38
 and the Diagnostic and Statistical Manual (DSM) 12
 and epidemiology 120
 and expertise 150
 history of 63, 105
 integration into medicine 5, 6–7
 molecular turn in 4
 in North America 6, 39
 and phenomenology 63
 and political transformation in Argentina 49
 problems of legitimacy 6
 and production of individuals 87
 reform of 8
 reform in Argentina 74
 and religion 71, 106
 role of psychiatrist 106, 110, 112
 stabilization of objects 3, 38
- psychic structure 9, 47, 87, 94–6, 104, 133
 and medication 164–7
 and patient narratives 88
- psychoanalysis 2, 8, 96
 and the analytic scene 94
 and authoritarianism 53

- and biomedical norms 125
- comparison with the natural sciences 93
- as a “conjectural science” 86
- as an ethical project 127
- history of 74–5, 161
- history in Buenos Aires 15
- Lacanian 40, 73, 90
- and patient narratives 87, 88–90, 100
- and psychopharmacology 8–9
- in public hospitals 14, 74–5
- Self-Analysis 92, 93
- and social rights 68
- and subjectivity 87
- psychodynamic humanism 106
- psychopharmaceuticals
 - anti-psychotics 23, 50, 51, 58, 72, 98, 112, 114, 116, 117, 129, 131, 149, 165, 166
 - anxiolytics 115, 151, 152
 - development of 7
 - and mental illness 128–33
 - neuroleptics 59, 64, 114, 115, 132
 - rate of consumption and economic crisis 153–4
 - sales of 29–30, 142, 152–7, 158
 - see also* anti-depressants; mood stabilizers, tranquilizers
- psychopharmacology 8–9, 70, 84
 - and risk 126
 - and *Salud Mental* 47
 - and subjectivity 84
 - and the therapeutic trial 163
- psychopathology 46
- psychosis 95, 96, 130
 - see also* Freud, Sigmund
- psychotherapy 109
- public health 73, 98
 - in Argentina 14
 - and data collection 19
 - and government 136
 - and psychoanalysis 68
- public hospitals 1, 40, 48, 49, 52, 88, 141
 - and Lacanian psychoanalysis 74
 - Hospital Moyano 50, 81, 100
 - Hopital Pirobano 77, 78, 79, 126
 - and psychoanalysis 82–3
 - sales reps in 141
 - see also* Hospital Borda; Hospital Romero
- Rabinow, Paul 31
- rationality, forms of 10, 41
 - administrative 121–3
 - biomedical 15, 71
 - of health administration 14
 - shifts in 121
- rationalization processes 71, 170
- regulation 157–9, 175
 - Buenos Aires city government 24
 - informal 136
 - post-social 141–4
 - and production of liquidity 21
 - of research in Argentina 28
- Research Diagnostic Criteria (RDC) 11, 174
- Rhodes, Lorna 81
- Ricón, Lía 58, 59, 60, 61, 67, 165
- risk 81, 112
 - and genomics 30–2
 - individualized management of 30–1
 - and political rationality 108, 121
 - and populations 122
 - and psychopharmacology 126
- Rose, Nikolas 31, 44, 107, 110
- Rosenberg, Charles 10
- Roses, Allen 171, 173
- Salud Mental* 15, 44, 48, 49, 53, 65, 67, 69, 71, 75, 76, 77, 118, 150
 - critiques of 55
 - and globalization 69
 - history of 44–7
 - and managed care 124
 - radicalization of 49
- Sarlo, Beatriz 16
- schizophrenia 21, 22, 33, 58, 97, 104, 129, 174
 - in Argentina 117
 - schizophrenia paradigm 112
 - schizophrenia-bipolar gene 161, 168
 - in United States 34
- self-care 107, 108, 110, 111
- Sigal, Silvia 75
- SNPs (Single Nucleotide Polymorphisms) 24
 - SNP Map 23, 171
- SNP Consortium 171, 172, 180
- social, the 44, 46
- social psychiatry 8, 47, 105, 150
- social psychology 45
- sociobiology 31
- Sokal, Alan 73
- Soler, Colette 80
- specificity model 7, 10, 11, 163, 173, 174
 - critiques of 65
- Stagnaro, Juan Carlos 43, 57, 62, 135, 150, 152

Cambridge University Press

0521546664 - Pharmaceutical Reason: Knowledge and Value in Global Psychiatry

Andrew Lakoff

Index

[More information](#)

206

Index

- standardization 10, 11–12, 18, 32, 35, 122, 143
 and liquidity 21
 obstacles to 39
 of psychiatric measures 36
 and psychoanalysis 92
- Star, Susan Leigh 13
- statistics 24, 120, 122, 136
- Stengers, Isabelle 92, 94
- Stevens, Mitchell 61
- Stinchcombe, Arthur 21
- strategic consulting 168
 history of 168
 as a post-social science 169
- structuralist dualism 83–6, 101
- style of reasoning 87
- subjectivity 68, 70, 85, 86, 108
 and authority 94
 and medication 102
 and neoliberalism 62
 of patients 83–4
 and psychopharmacology 84
- Swain, Gladys 5
- technology 170, 171, 173, 174, 175
 as an adaptive organ 176
 and dehumanization 176
 and ethics 14
 and the human 14–16, 175
- therapeutic community 47
- therapeutic trial 161–4
- thinking in cases 87
- tranquilizers 135, 155, 156
- transference 92, 93, 94, 95
- TRIPs (Trade Related Aspects of Intellectual Property Rights) Accord 138
- underdevelopment 55–7, 103
- United States Patent and Trademark Office (USPTO) 29, 160
- University of Buenos Aires 73, 78, 80, 127, 147
- value 20, 161, 172
 and liquidity 21
 relations with truth 20
 and science 23–4
- Vertex* 43, 70
- Vezzetti, Hugo 55, 66, 67
- Vidal, Guillermo 46, 64, 71
- Visacovsky, Sergio 66
- Weber, Max 14, 71
- welfare state 137, 138
- Wellcome Trust 171
- Winkelman, William 8
- World Bank 123
- World Health Organization (WHO) 32, 45, 157
- World Psychiatric Association 64, 148
- World Trade Organization (WTO) 151